WACKER’s mRNA competence center in Halle is to produce an active ingredient based on mRNA and lipid nanoparticles (LNPs) for combating acute respiratory distress syndrome (ARDS).
Wacker Chemie AG and the Technical University of Munich (TUM) have deepened their partnership with the founding of the TUM WACKER Institute for Industrial Biotechnology. The goal of the new institute is to further develop research in the field of industrial biotechnology in Germany at the highest international level. The two partners will bring their combined forces to bear on researching new approaches for the production of specialty chemicals and active ingredients from renewable resources as a basis for a sustainable economic system. Wacker will provide the institute with more than €6 million in research funds over the contractually agreed term of six years. The new institute will begin its work in the 2022/2023 winter semester.
BERLIN, July 5 (Reuters) - Chemicals group Wacker Chemie (WCHG.DE) has commissioned construction firm Exyte to build a plant for mRNA components, a medical technology first widely used in COVID-19 vaccines, in an investment of 100 million euros ($102.97 million).
As a consequence of the initial vaccine shortages in the coronavirus pandemic, the German government is securing vaccine production and supplies for the years ahead. Pharmaceutical producers with appropriate vaccine expertise and capacity were invited to apply for stand-by production agreements with the German government. As joint bidders, Wacker and CordenPharma applied for the stand-by production of vaccines based on messenger ribonucleic acid (mRNA).
Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors
The global demand for nucleic acid-based gene therapies, novel vaccines, and innovative therapeutic agents including messenger RNA (mRNA) and viral vectors is extremely high and projected to increase in the future. Plasmid DNA (pDNA) is the basis for all these advanced therapies as it can be used either directly for gene therapies and vaccines, or as starting material, for example to manufacture mRNA. The CDMO market for pDNA is expected to grow by 19 percent by 2025 (Global Viral Vector and Plasmid DNA Manufacturing Market Research Report). Wacker Biotech US offers decades of experience and expertise in all aspects of pDNA technology.
Wacker Biotech US Inc. is the new name of Genopis Inc., the plasmid DNA manufacturer based in San Diego, CA, that Wacker acquired in February. The acquisition concerns a plasmid DNA (pDNA) CDMO site and its associated business.
The Munich, Gemany-based chemical company Wacker is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis from South Korea-based firms Helixmith and Medivate Partners. Wacker will continue Genopis' existing customer relationships as a contract development and manufacturing organization (CDMO) for plasmid DNA (pDNA). The total purchase price for the acquisition consists of a $39 million cash payment due upon closing as well as possible further performance-based payments under a so-called earn-out model. The transaction is expected to close in the first quarter of 2021.
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG have signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.
Wacker Chemie, a chemical company based in Munich, purchased a Dutch biopharma manufacturing site and associated business from SynCo Bio Luxembourg for an undisclosed price.